Morgan Stanley’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-10,725
| Closed | -$3K | – | 8111 |
|
|
2022
Q3 | $3K | Sell |
10,725
-1
| -0% | – | ﹤0.01% | 7437 |
|
|
2022
Q2 | $4K | Sell |
10,726
-1,407
| -12% | -$712 | ﹤0.01% | 7489 |
|
|
2022
Q1 | $8K | Sell |
12,133
-1,774
| -13% | -$1.95K | ﹤0.01% | 7486 |
|
|
2021
Q4 | $32K | Buy |
13,907
+3,215
| +30% | +$10.9K | ﹤0.01% | 7018 |
|
|
2021
Q3 | $49K | Sell |
10,692
-7,363
| -41% | -$32.4K | ﹤0.01% | 6740 |
|
|
2021
Q2 | $80K | Buy |
18,055
+8,991
| +99% | +$45.7K | ﹤0.01% | 6452 |
|
|
2021
Q1 | $66K | Sell |
9,064
-14,671
| -62% | -$121K | ﹤0.01% | 6219 |
|
|
2020
Q4 | $181K | Buy |
23,735
+16,607
| +233% | +$111K | ﹤0.01% | 5645 |
|
|
2020
Q3 | $65K | Buy |
7,128
+413
| +6% | +$3.13K | ﹤0.01% | 5620 |
|
|
2020
Q2 | $56K | Buy |
6,715
+3,253
| +94% | +$21.4K | ﹤0.01% | 5644 |
|
|
2020
Q1 | $17K | Sell |
3,462
-39,741
| -92% | -$309K | ﹤0.01% | 5875 |
|
|
2019
Q4 | $311K | Buy |
43,203
+39,505
| +1,068% | +$357K | ﹤0.01% | 5194 |
|
|
2019
Q3 | $40K | Buy |
3,698
+3,670
| +13,107% | +$39.3K | ﹤0.01% | 5809 |
|
|
2019
Q2 | $0 | Sell |
28
-1,411
| -98% | -$18.7K | ﹤0.01% | 6817 |
|
|
2019
Q1 | $14K | Sell |
1,439
-10,985
| -88% | -$102K | ﹤0.01% | 6115 |
|
|
2018
Q4 | $129K | Buy |
+12,424
| New | +$150K | ﹤0.01% | 5449 |
|
Morgan Stanley's LOGC Position: Q4 2022 in Review
Morgan Stanley sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 10,725 shares — an estimated $3K sold.
Morgan Stanley first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $311K in Q4 2019. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Morgan Stanley reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Morgan Stanley sold 10,725 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $3K.
- Morgan Stanley first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- Morgan Stanley's LogicBio Therapeutics, Inc. Common Stock position peaked at $311K in Q4 2019.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.